Navigation Links
Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
Date:9/17/2011

n July 2009, Amgen and GlaxoSmithKline announced a collaboration agreement to jointly commercialize Prolia for postmenopausal osteoporosis in Europe, Australia, New Zealand and Mexico once the product is approved in these countries. Amgen will commercialize Prolia's postmenopausal osteoporosis and potential oncology indications in the U.S. and Canada and for all oncology indications in Europe and in other specified markets.

In addition, GlaxoSmithKline will register and commercialize denosumab for all indications in countries where Amgen does not currently have a commercial presence, including China, India and South Korea but excluding Japan. The structure of the collaboration allows Amgen the option of an expanded role in commercialization in both Europe and certain emerging markets in the future.

Amgen and Daiichi Sankyo Company, Limited have a collaboration and license agreement for the development and commercialization of denosumab in Japan.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.  Follow us on www.twitter.com/amgen.

Forward-Looking Statements

This news release contains forward-looking statements that are based on management's current expectations
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
2. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
3. XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
4. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
5. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
6. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
7. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
8. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
9. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
10. Vantage Health Announces That All of Its Required Tanzanian Registrations, Permits and Licenses Have Been Formally Issued, Simultaneous With Official Notification That Its Application for Phase One Evaluation of Its HIV Screening Test Kits Has Been
11. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Ill. , Aug. 3, 2015 Your ... problem, and you,re looking for the best possible outcome. ... the best outcome too, and now there,s a ... Following steps recommended by the American Orthopaedic Foot ... surgery can help you avoid complications and heal as ...
(Date:8/3/2015)... , Aug. 3, 2015 Par Pharmaceutical ... conference call on Friday, August 7, 2015 at 9:00 ... the second quarter ended June 30, 2015.  Par is ... to the public in its filings with the Securities ... available on its website by following the instructions at ...
(Date:8/3/2015)... N.J. , Aug. 3, 2015 Ortho ... has been named Chief Corporate Brand and Communications ... firm,s executive leadership team, Bouryal will lead the company,s ... builds on its transition to an independent company by ... report to Chairman and Chief Executive Officer Dr. ...
Breaking Medicine Technology:Patient Guide: How to Prepare for Surgery 2Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2
... 22 Dynavax,Technologies Corporation (Nasdaq: DVAX ) today ... ragweed allergy therapy, to subjects as,part of an environmental ... of 300 subjects. Subjects are being screened based on ... Exposure to ragweed allergen in,the chamber is being used ...
... 22 Boston,Scientific Corporation (NYSE: BSX ) ... which continue to support the proven safety and,efficacy ... and add to the growing body of strong ... Coronary,Stent System. An analysis of the data was ...
Cached Medicine Technology:Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 2Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 3Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures 2Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures 3Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures 4
(Date:8/3/2015)... ... August 03, 2015 , ... Results ... Navigant Center for Healthcare Research and Policy Analysis show widespread support for the ... said they agreed or strongly agreed that the controversial law passed in 2010 ...
(Date:8/3/2015)... ... August 03, 2015 , ... It’s 25 miles from ... California’s northernmost and among its least visited State Parks. The volcanic area beneath ... outflow is at Ahjumawi Lava Springs, part of the Fall River Springs complex. ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article from The Daily ... to Release Natural Painkiller That Can Last 'For Five Weeks'" discusses the use ... the new study showed that harvesting stem cell-rich bone marrow from the hip, known ...
(Date:8/3/2015)... AZ (PRWEB) , ... August 03, 2015 , ... Dignity ... Dignity Health Arizona General Hospital Emergency Room – Gilbert, opening in August. The ... earlier this year in the West Valley. , “Dr. Baldwin is an excellent ...
(Date:8/3/2015)... ... 2015 , ... Cambia Health Solutions has promoted Scott Powers ... Medicare and Federal Employee Programs (FEP) lines of business. , Government programs ... In this role, Scott is responsible for overseeing the growth, finance and operations ...
Breaking Medicine News(10 mins):Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
... Pharmasset, Inc.,(Nasdaq: VRUS ) management will present ... being held from May 19-20, 2008 at the Le,Meridien ... Chief Executive Officer, will provide an overview of the,company ... in the Zephyr Salon., To access a simultaneous ...
... Foundation to celebrate,scientific advancements that have fueled longer life ... To celebrate,remarkable progress in treating cystic fibrosis -- ... the Cystic Fibrosis Foundation,to join the company as honored ... Life expectancy for people with CF has more than ...
... Company Prepares for, Potential 2008 Launch of MOXATAG; Keflex Product Sales ... ... in Quarter, GERMANTOWN, Md., May 13 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: ... anti-infective products, today,announced financial and operational results for the quarter ended ...
... impact EPA,s clean air regulations, researchers say , , TUESDAY, ... particles, such as those found in windblown dust or ... not appear to be linked to hospital admissions, a ... for short, is between 2.5 and 10 micrometers or ...
... studies report, , , TUESDAY, May 13 (HealthDay News) -- New ... breast cancer risk. , The bad news is a ... with breast cancer face an increased risk of breast cancer ... according to a study in the May 13 issue of ...
... used to treat a rare but well-known genetic disorder may ... with potentially lethal enlarged hearts, due mainly to high blood ... The common denominator in both phenylketonuria (PKU) and cardiac hypertrophy ... coworker helps break down the molecule phenylalanine whose buildup is ...
Cached Medicine News:Health News:Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th 2Health News:Cystic Fibrosis Foundation President Rings Bell to Close New York Stock Exchange 2Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 2Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 3Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 4Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 5Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 6Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 7Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 8Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 9Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 10Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 11Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 12Health News:MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results 13Health News:No Link Between Coarse Air Pollution, Hospitalizations 2Health News:Familial Breast Cancer Risk Lasts a Lifetime for Sisters 2Health News:Familial Breast Cancer Risk Lasts a Lifetime for Sisters 3Health News:Drug therapy for PKU reverses heart damage 2Health News:Drug therapy for PKU reverses heart damage 3Health News:Drug therapy for PKU reverses heart damage 4
96 well format, Gradient features tests 12 PCR annealing temperatures in 1 run...
... Family offers fast temperature control, exact block ... Personal cards enable safe program storage as ... individual protocols between different Mastercyclers. All models ... come with a two-year warranty. The ...
... 96 well thermocycler with ... Peltier technology for fastest available ... to 4C/sec with High Pressure ... PCR plates. Includes motorized ...
... graphical touch screen display which enables you ... of a screen." Features & Benefits ... Graphical Display, Memory Cards, Gradient Calculator, Fold ... Programmin, Free Instrument Software Upgrade. Includes ...
Medicine Products: